Researchers report that the number of people in the U.S. who died from ischemic heart disease related to obesity increased by approximately 180% from 1999 to 2020. The… read more.
Autolus Therapeutics announces the online publication of four abstracts submitted to the American Society of Hematology (ASH) Annual Meeting, to be held from December 7-10, 2024, in San… read more.
Alkermes announced the presentation of research related to Lybalvi (olanzapine and samidorphan) and Aristada (aripiprazole lauroxil), the company’s commercial products in psychiatry, and ALKS 2680, an investigational medicine… read more.
GlycoMimetics, Inc. announced that data from multiple clinical trials studying uproleselan in patients with acute myeloid leukemia (AML) have been accepted for presentation at the 66th American Society of… read more.
Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Jaypirca® (pirtobrutinib), a non-covalent (reversible) Bruton’s tyrosine kinase (BTK) inhibitor, will be presented at the 66th American Society of… read more.
Gilead Sciences, Inc announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2024), taking place from November… read more.
Kite, a Gilead Company (Nasdaq: GILD), will share 18 presentations, including six oral presentations, demonstrating the strength of its CAR T-cell therapy portfolio across a spectrum of blood… read more.
Genentech, a member of the Roche Group, announced that it will present more than 40 abstracts across nine blood disorders at the 66th American Society of Hematology (ASH)… read more.
Marsha Showman and Reena Patel (Leeds Health and Care Partnership) presented a poster describing how utilisation of health services was improved when people with long term conditions, including… read more.
Arrowhead Pharmaceuticals, Inc. announced that it is scheduled to participate in the following upcoming events: 15th Annual American Conference on Pharmacometrics (ACoP 2024) – November 10-13, 2024 Title: Population K-PD Modeling of… read more.
In his keynote lecture Richard Cattell, Deputy Chief Pharmaceutical Officer, asked pharmacists to do three things: Make their voices heard in the development of the NHS 10-year plan… read more.
Eli Lilly and Company announced that data from the Phase III trial (EMBER-3) for imlunestrant, an oral selective estrogen receptor degrader (SERD), will be reported for the first… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
